Leronlimab

Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against CytoDyn Inc. (CYDY)

Retrieved on: 
Wednesday, May 12, 2021
Legal, Professional services, Contemporary history, Health, Leronlimab, Infectious diseases, Topaz, COVID-19 pandemic, Topaz

For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.

Key Points: 
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Since the beginning of the global COVID-19 pandemic, CytoDyn began aggressively touting Leronlimab as a treatment for COVID-19.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005044/en/\n'

Scott+Scott Attorneys at Law LLP Alerts Investors with Losses Over $250,000 to Securities Class Action Against CytoDyn, Inc. (CYDY)

Retrieved on: 
Wednesday, May 12, 2021
Companies, Leronlimab, Security, BlackBerry Limited, AT&T, Clinical endpoint

In these releases, CytoDyn disclosed that the primary endpoint for the Leronlimab study (all-cause mortality at Day 28) was not statistically significant.

Key Points: 
  • In these releases, CytoDyn disclosed that the primary endpoint for the Leronlimab study (all-cause mortality at Day 28) was not statistically significant.
  • Upon the opening of trading, CytoDyn shares dropped over 28% to close at $2.91 on March 8, 2021.
  • The lead plaintiff deadline is May 17, 2021.\nScott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.
  • The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.\n'

CYDY Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: May 17, 2021

Retrieved on: 
Monday, May 10, 2021
XC2, Gewirtz, Bronstein, Leronlimab, Grossman

The CEO has made inappropriate promotional claims like \xe2\x80\x98this looks the solution to coronavirus\' leading into his most recent stock sale.

Key Points: 
  • The CEO has made inappropriate promotional claims like \xe2\x80\x98this looks the solution to coronavirus\' leading into his most recent stock sale.
  • "\xc2\xa0The report alleged that the company is a "big joke" regarding its claim to have developed a cure for COVID-19 with "zero" data related to over-hyped leronlimab.
  • If you wish to review a copy of the Complaint you can visit the firm\xe2\x80\x99s site: www.bgandg.com/cydy or you may contact Peretz Bronstein, Esq.
  • or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.

Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc.

Retrieved on: 
Thursday, May 6, 2021
Leronlimab, Topaz, XC2, Topaz, Whistleblower, Articles, Human rights, Creative works

For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.

Key Points: 
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Since the beginning of the global COVID-19 pandemic, CytoDyn began aggressively touting Leronlimab as a treatment for COVID-19.
  • \xc2\xa0The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).\xc2\xa0 The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .\nKessler Topaz Meltzer & Check, LLP\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)

Retrieved on: 
Monday, May 3, 2021
Leronlimab, Equity securities, Stock market, Share

Masked by positive titles, these releases disclosed that the primary endpoint for the study (lowering all-cause mortality at Day 28) was not statistically significant.\nOn this news, the Company\xe2\x80\x99s share price fell $1.14 per share, or 28%, to close at $2.91 on March 8, 2021.

Key Points: 
  • Masked by positive titles, these releases disclosed that the primary endpoint for the study (lowering all-cause mortality at Day 28) was not statistically significant.\nOn this news, the Company\xe2\x80\x99s share price fell $1.14 per share, or 28%, to close at $2.91 on March 8, 2021.
  • On March 9, 2021, CytoDyn shares dropped an additional 19% to close at $2.35, thereby injuring investors further.\nThe complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements touting Leronlimab as a potential treatment for COVID-19 to pump up the CytoDyn\xe2\x80\x99s stock price while executives aggressively sold their shares.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. (CYDY)

Retrieved on: 
Monday, May 3, 2021
Contemporary history, Health, Leronlimab, Infectious diseases, Topaz, Topaz, COVID-19 pandemic

For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.

Key Points: 
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Since the beginning of the global COVID-19 pandemic, CytoDyn began aggressively touting Leronlimab as a treatment for COVID-19.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .\nKessler Topaz Meltzer & Check, LLP\n'

CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results

Retrieved on: 
Monday, May 3, 2021
HIV/AIDS, Health sciences, Health, Retroviridae, Leronlimab, Sexually transmitted diseases and infections, Clinical trial, HIV, CCR5 receptor antagonist

Clinical results from multiple trials show that Vyrologix can significantly reduce the viral burden in people infected with HIV.

Key Points: 
  • Clinical results from multiple trials show that Vyrologix can significantly reduce the viral burden in people infected with HIV.
  • CytoDyn has gained tremendous insight in the safety of Vyrologix through extension of their three core HIV trials.
  • There have been 66 patients from the original trials still receiving Vyrologix in an open label design with an exposure range of 4-7 years.
  • Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans.

Data from 10 Patients with Stage Four Cancer Treated with Leronlimab for Nearly One Year Will Serve as Basis for Pre-Breakthrough Therapy Designation Meeting with FDA

Retrieved on: 
Monday, May 3, 2021
HIV/AIDS, Medical specialties, Entry inhibitors, Leronlimab, Immune system, CCR5, Branches of biology, CCR5 receptor antagonist, HIV

We look forward to accelerating our efforts in the oncology field with leronlimab.

Key Points: 
  • We look forward to accelerating our efforts in the oncology field with leronlimab.
  • It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans.
  • CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.

CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple Initiatives

Retrieved on: 
Monday, May 3, 2021
Leronlimab, CCR5, Immune system, Branches of biology, Immunology

b'VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (\xe2\x80\x9cCytoDyn\xe2\x80\x9d or the \xe2\x80\x9cCompany"), a late-stage biotechnology company developing Vyrologix\xe2\x84\xa2 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Chris Recknor, M.D., Chief Operating Officer will host an investment community webcast on Wednesday, May 5, 2021.\nManagement will provide a full update to its stockholders on Company priorities, including recent COVID-19 initiatives and additional information concerning its active trials in COVID-19, NASH and cancer.\nManagement will dedicate approximately 60 minutes to address questions submitted online by analysts and investors.\nDuring the webcast, questions can be submitted through the webcast link below.\nThis is a \xe2\x80\x9clisten only\xe2\x80\x9d webcast, which can be accessed via CytoDyn\xe2\x80\x99s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days.

Key Points: 
  • b'VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (\xe2\x80\x9cCytoDyn\xe2\x80\x9d or the \xe2\x80\x9cCompany"), a late-stage biotechnology company developing Vyrologix\xe2\x84\xa2 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Chris Recknor, M.D., Chief Operating Officer will host an investment community webcast on Wednesday, May 5, 2021.\nManagement will provide a full update to its stockholders on Company priorities, including recent COVID-19 initiatives and additional information concerning its active trials in COVID-19, NASH and cancer.\nManagement will dedicate approximately 60 minutes to address questions submitted online by analysts and investors.\nDuring the webcast, questions can be submitted through the webcast link below.\nThis is a \xe2\x80\x9clisten only\xe2\x80\x9d webcast, which can be accessed via CytoDyn\xe2\x80\x99s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days.
  • Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software.
  • Please note the below webcast link will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:\nThe replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until June 5, 2021.\n'

Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc.

Retrieved on: 
Sunday, May 2, 2021
Leronlimab, Topaz, Topaz

For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.

Key Points: 
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Since the beginning of the global COVID-19 pandemic, CytoDyn began aggressively touting Leronlimab as a treatment for COVID-19.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .\nKessler Topaz Meltzer & Check, LLP\n'